Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

Licensed from the Dana-Farber Institute, Cosibelimab is a fully-human anti-PD-L1 mAb with a dual mechanism of action Safe Harbor Statement This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act ...